Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Greg Plunkett, Founder and CEO of Accelagen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Greg, covering:

How years at big pharma exposed him to the full journey from concept to commercialisation.

Why stepping into a smaller organisation gave him the practical tools and confidence to start his own venture.

How following market signals into regulatory consulting, while being a stay at home dad, became the foundation for Accelagen.

Why trust, referrals and long term relationships have driven sustainable growth.

How Australia’s clinical trial ecosystem offers quality, speed and tax advantages that attract global innovators.

What it takes to guide small to mid sized biotech companies from discovery all the way to market.

Greg Plunkett is the Founder and CEO of Accelagen, a full service regulatory affairs and clinical development CRO headquartered in Melbourne, Australia. His career spans almost 30 years across both big and small pharma and biotech organisations before founding Accelagen in 2010. He has supported local and international companies in developing new technologies from discovery through to commercialisation.

Greg leads a highly experienced team across Australia, New Zealand and the United States, united by a mission to make a meaningful difference to the future of human health.

He holds a Masters of Medical Science from the University of New South Wales and postgraduate business qualifications.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Joerg Ahlgrimm, CEO SK pharmteco.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Joerg, covering:

 

His journey from East Germany to leading global manufacturing organisations.

How building and integrating acquired CDMO relationships ultimately led him to Lonza, where he helped scale the manufacturing network from fifteen to thirty five sites worldwide.

What he learned about the “sticky” nature of the CDMO business, and the unforgiving reality of being a CDMO partner when execution does not go to plan.

The leap from the scale and structure of Lonza in Basel to becoming employee number four at a CDMO start up in Philadelphia.

Why his vision for a small molecule CDMO is to be easy to work with and present across the key global manufacturing regions.

Why, despite the rise of blockbuster GLP one therapies, he believes the future lies in small volume, highly targeted, and complex to manufacture personalised medicines.

 

Joerg Ahlgrimm is a global operations and supply chain executive with more than 25 years of leadership experience across the biotech, pharmaceutical, vaccines, and medical device industries. As CEO of SK pharmteco, he leads the company’s strategic growth and operational excellence across its global manufacturing network.

 

Prior to SK pharmteco, Joerg served as Head of Global Operations, Pharma and Biotech at Lonza AG, where he oversaw 37 sites worldwide. Earlier, he led the manufacturing network for Baxter Bioscience/Baxalta, managing a broad global footprint and extensive CMO operations.

 

Driven by a passion for advancing patient care, Joerg is recognized for building high-performing teams and navigating complex global supply chains. He was recently appointed to the inaugural Strategic Advisory Board of BioPhorum, joining senior industry leaders to help shape the future of pharmaceutical manufacturing and supply chain resilience.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring the overlooked trends for 2026.

 

Nick Fortin, CEO, Codis

Ankit Gupta, CEO, InstaPill

Eric Edwards, MD, PhD, CEO, Phlow USA

Dirk T. Lange, CEO, Pyramid Pharma Services

Kaan-Fabian Kekec, Partner, Simon-Kucher Healthcare and Life Sciences

J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals

Matthew Bio, CSO, Cambrex and President, Snapdragon Chemistry

Bill Vincent, Biotech Entrepreneur, CEO and Board Member

Philip Macnabb, CEO, Curia

Christiane Bardroff, COO Leader

Jason Anderson, CEO, Ensera

Mark B, Anonymous CEO (not to be quoted by name)

Adam Siebert, Managing Director, L.E.K. Consulting

Stephen Dilly, CEO, Sonoma Biotherapeutics

Elisabeth Stampa, CEO, Medichem

Jon Alberdi, CEO, Vivebiotech

Derek Hennecke, Founder, Investor and Board Member

Bruce Thompson, CTO, Kincell Bio

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Banks Bourne, Founder & Chief Executive Officer at Bourne Partners.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Banks, covering:

 

How making a bet in the right place at the right time sparked an extraordinary journey in pharma investing.

The founding of Bourne Partners and a twenty five plus year ride through multiple market cycles.

Lessons from hundreds of deals, and why the best investments are often the most complex and hardest won.

Why running from ego and listening obsessively to clients is one of the most underrated advantages in private equity.

Why private equity has become increasingly commoditised, and why Banks believes momentum is building and sentiment is turning positive heading into 2026.

As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners. He and the firm have been party to more than $10 billion of transactions in the pharmaceutical (“pharma”), pharma services, and consumer healthcare sectors. Banks is also the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization, and clinical trials services to patients and partners in more than 100 countries.

 

For almost 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jump started his interest in the healthcare sector. Since then, he has invested in more than 200 private companies / assets.

 

While Banks has derived great satisfaction by offering focused advisory services to, and investing in, pharma, healthcare, and consumer-oriented companies that need strategic and operational insights, he is even more gratified knowing that his work has helped companies to improve the health and well-being of patients across the world. Banks is passionate about providing healthcare, and specifically pharmaceuticals, to less fortunate patients, as demonstrated by supporting The Max Foundation, Partners in Health, The Bourne Foundation, The Levine Children’s Hospital, and other non-profit organizations. He received a B.A. degree in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO).

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Julian Casciano, President & CEO at eMAX Health.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julian, covering:

 

How a family tragedy led him into the healthcare and pharmaceutical world.

Why corporate life was not for him, but the valuable lessons he learned during his time at KPMG.

The turbulent journey with a venture capital partner that ultimately led to an IPO and a successful first exit.

How a relentless drive to become truly technology enabled has resulted in sixty percent of company revenue now coming from tech driven solutions.

What led him to partner with private equity to accelerate investment in a game changing technology platform.

Why the future of the sector is unfolding at speed right in front of us, and why now is the time to jump on board.

 

As Chairman and Chief Executive Officer, Julian leads eMAX Health’s mission to modernize market access and patient services for pharmaceutical and biotech innovators. With a background in technology enabled pharmaceutical services, commercialization strategy, patient services, and entrepreneurship, he has built the organisation into a trusted partner for navigating the complexity of rapidly evolving medical and commercial programs.

 

Most recently, Julian spearheaded the launch of MAVA®, a proprietary digital platform delivering rapid stakeholder insights and pricing guidance powered by real time data and AI. He also architected eMAX Health’s proprietary patient services case management system, HealthPACER®.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!